Harvard Bioscience, Inc.

$5.40+7.78%(+$0.39)
TickerSpark Score
36/100
Weak
60
Valuation
40
Profitability
10
Growth
40
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HBIO research report →

52-Week Range39% of range
Low $2.80
Current $5.40
High $9.50

Companywww.harvardbioscience.com

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments.

CEO
John Duke
IPO
2001
Employees
330
HQ
Holliston, MA, US

Price Chart

+60.71% · this period
$7.87$5.36$2.84May 20Nov 18May 20

Valuation

Market Cap
$24.35M
P/E
-2.47
P/S
0.28
P/B
2.40
EV/EBITDA
36.19
Div Yield
0.00%

Profitability

Gross Margin
57.06%
Op Margin
1.39%
Net Margin
-11.44%
ROE
-73.04%
ROIC
2.11%

Growth & Income

Revenue
$86.55M · -8.06%
Net Income
$-56,700,000 · -357.07%
EPS
$-12.80 · -357.14%
Op Income
$-629,000
FCF YoY
408.01%

Performance & Tape

52W High
$9.50
52W Low
$2.80
50D MA
$5.66
200D MA
$5.59
Beta
1.57
Avg Volume
53.66K

Get TickerSpark's AI analysis on HBIO

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Mar 20, 26Frost Mark Tother30,000
Mar 16, 26Frost Mark Tbuy5,000
Mar 20, 26Duke John Dother75,000
Mar 17, 26DENELSKY STEPHEN Jbuy10,000
Mar 17, 26Snider Williambuy8,475
Mar 16, 26Snider Williambuy12,525
Mar 16, 26Duke John Dbuy5,000
Dec 17, 25Snider Williamother110,000
Dec 17, 25Snider Williamother600,000
Sep 5, 25DENELSKY STEPHEN Jother110,000

Our HBIO Coverage

We haven't published any research on HBIO yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate HBIO Report →

Similar Companies